White paper: Aseptic filling for personalized medicines
Vanrx Pharmasystems has released Aseptic Filling for Personalized Medicines, a white paper that reviews how new agile filling technology can change the manufacturing of cell and gene therapies.
Aseptic Filling for Personalized Medicines describes a solution for the aseptic filling of cell and gene therapies, immuno-oncology, mRNA and other modalities where manufacturing creates a therapy for a single patient. New technologies that automate the production of personalized medicines will be critical to both their clinical efficacy and commercial viability.
The solution introduced is a gloveless robotic isolator, a machine that performs automated vial filling and closure for small batches of sterile injectables. These tasks are performed within the small space of a completely closed isolator that maintains aseptic conditions. This new technology provides many benefits, including:
- Cost-effectiveness: build clinical and development filling capacity at a lower cost and in less time.
- Agility: fill up to four products in a single day. Can fill 2R-50R nested vials with toolless changeover and decontamination in 15 minutes.
- Standard design: allows companies can scale quickly to meet commercial demand.
Vanrx was founded by experts in biopharmaceutical development and manufacturing. The company designs and manufactures Aseptic Filling Workcells—gloveless robotic isolators.
About Vanrx Pharmasystems
Vanrx Pharmasystems makes the most technologically advanced sterile filling solutions for the pharmaceutical industry. Vanrx fill-finish machines use isolated robotics and machine vision to automate the packaging of injectable drugs into nested vials, syringes, or cartridges. The company was founded by pharmaceutical industry veterans to create the systems needed to make the next generation of innovative therapies. For more information, visit www.vanrx.com.